TerminatedPhase 2NCT04732429
Study of HST5040 in Subjects With Propionic or Methylmalonic Acidemia
Studying Disorder of branched-chain amino acid metabolism
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- HemoShear Therapeutics
- Principal Investigator
- Patrick Horn, MD PhDHemoShear Therapeutics, Inc.
- Intervention
- HST5040(drug)
- Enrollment
- 26 enrolled
- Eligibility
- 2 years · All sexes
- Timeline
- 2021 – 2023
Study locations (16)
- Rady Children's Hospital, San Diego, California, United States
- Yale, New Haven, Connecticut, United States
- Children's National Health System, Washington D.C., District of Columbia, United States
- Emory University School of Medicine, Atlanta, Georgia, United States
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
- Boston Children's Hospital, Boston, Massachusetts, United States
- University of Minnesota, Minneapolis, Minnesota, United States
- Children's Mercy Hospital Kansas City, Kansas City, Missouri, United States
- University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
- Nationwide Children's Hospital, Columbus, Ohio, United States
- University of Pittsburgh Medical Center - Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
- Vanderbilt University Medical Center, Nashville, Tennessee, United States
- John P. and Kathrine G. McGovern Medical School, Houston, Texas, United States
- University of Utah Hospital, Salt Lake City, Utah, United States
- Royal Children's Hospital Melbourne, Parkville, Victoria, Australia
- +1 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04732429 on ClinicalTrials.govOther trials for Disorder of branched-chain amino acid metabolism
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07573059Evaluation of the Safety of Loargys Arginine Test System in Loargys-treated PatientsImmedica Pharma US Inc
- ENROLLING BY INVITATIONNANCT06953505At Home Ammonia Monitoring of Inborn Errors of Ammonia MetabolismSequitur Health Corp.
- RECRUITINGNCT05040178An Observational Study of Carbaglu® for the Treatment of MMA and PA in Adults and PediatricsRECORDATI GROUP
- RECRUITINGPHASE1, PHASE2NCT05130437A Study to Assess the Long-term Safety and Clinical Activity of mRNA-3927 in Participants Previously Enrolled in the mRNA-3927-P101 StudyModernaTX, Inc.
- RECRUITINGPHASE1, PHASE2NCT04159103Open-Label Study of mRNA-3927 in Participants With Propionic AcidemiaModernaTX, Inc.
- RECRUITINGNCT04176523Understanding the Long-Term Management of Organic Acidemia Patients With CARBAGLU®: A Mixed Methods ApproachRECORDATI GROUP
- RECRUITINGNCT02890342Natural History, Physiology, Microbiome and Biochemistry Studies of Propionic AcidemiaNational Human Genome Research Institute (NHGRI)
See all trials for Disorder of branched-chain amino acid metabolism →